Literature DB >> 32775252

Conserving the lymphatics from the arm using fluorescence imaging in patients with breast cancer at high risk of postoperative lymphedema: a pilot study.

Kwang Hyun Yoon1, Sung Mook Lim2, Bonyong Koo3, Jee Ye Kim4, Hyung Seok Park4, Seho Park4, Seung Il Kim4, Byeong-Woo Park4, Young Up Cho5.   

Abstract

BACKGROUND: Postoperative lymphedema in breast cancer survivors is a serious complication that develops from axillary lymph node dissection (ALND), chemotherapy, and radiation therapy. Axillary reverse mapping (ARM) was recently introduced to reduce lymphedema. This pilot study aimed to investigate the feasibility of preserving the ARM node using fluorescence imaging for patients at high risk of lymphedema.
METHODS: We prospectively screened patients with breast cancer who had pathologic node-positive disease at diagnosis and were scheduled for neoadjuvant chemotherapy (NCT). The sentinel lymph node (SLN) was identified using blue dye and radioisotope, while the ARM node was traced using indocyanine green (ICG). In cases in which SLN was negative on the intraoperative frozen section examination, the ARM node and lymphatics were preserved.
RESULTS: Of the 20 screened patients, six whose metastatic axillary lymph node (ALN) was converted to clinically node-negative disease after NCT were enrolled. No patients experienced recurrence at 24 months postoperative. Four patients who had a preserved ARM node did not develop lymphedema. One patient whose ARM node was not preserved due to SLN identification failure did not develop postoperative lymphedema. One patient who underwent ALND without ARM node conservation because of metastatic SLN on frozen section examination developed postoperative lymphedema.
CONCLUSIONS: ARM is oncologically safe, decreases the incidence of postoperative lymphedema, and allows for the early detection of postoperative lymphedema in patients who underwent ALND. Ultimately, ARM may help improve the quality of life of patients with pathologic node-positive breast cancer. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Axillary reverse mapping (ARM); breast neoplasm; fluorescence imaging; indocyanine green (ICG); lymphedema

Year:  2020        PMID: 32775252      PMCID: PMC7347801          DOI: 10.21037/gs.2020.03.29

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  26 in total

Review 1.  Axillary reverse mapping for breast cancer.

Authors:  Masakuni Noguchi
Journal:  Breast Cancer Res Treat       Date:  2010-02       Impact factor: 4.872

2.  Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial.

Authors:  So-Youn Jung; Seok-Ki Kim; Seok Won Kim; Youngmee Kwon; Eun Sook Lee; Han-Sung Kang; Kyoung Lan Ko; Kyung Hwan Shin; Keun Seok Lee; In Hae Park; Jungsil Ro; Hae Jeong Jeong; Jungnam Joo; Se Hun Kang; Seeyoun Lee
Journal:  Ann Surg Oncol       Date:  2013-12-20       Impact factor: 5.344

3.  ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer.

Authors:  Christoph Hirche; Dawid Murawa; Zarah Mohr; Soeren Kneif; Michael Hünerbein
Journal:  Breast Cancer Res Treat       Date:  2010-02-07       Impact factor: 4.872

Review 4.  Adverse reactions to indocyanine green: a case report and a review of the literature.

Authors:  R Benya; J Quintana; B Brundage
Journal:  Cathet Cardiovasc Diagn       Date:  1989-08

5.  Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation.

Authors:  Margaret Thompson; Soheila Korourian; Ronda Henry-Tillman; Laura Adkins; Sheilah Mumford; Kent C Westbrook; V Suzanne Klimberg
Journal:  Ann Surg Oncol       Date:  2007-05-04       Impact factor: 5.344

6.  The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology.

Authors: 
Journal:  Lymphology       Date:  2016-12       Impact factor: 1.286

7.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

8.  Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection.

Authors:  Claude Nos; Benedicte Lesieur; Krishna B Clough; Fabrice Lecuru
Journal:  Ann Surg Oncol       Date:  2007-06-05       Impact factor: 5.344

9.  Axillary reverse mapping using fluorescence imaging is useful for identifying the risk group of postoperative lymphedema in breast cancer patients undergoing sentinel node biopsies.

Authors:  Takashi Sakurai; Mariko Endo; Ken Shimizu; Nobunari Yoshimizu; Kenichirou Nakajima; Kaori Nosaka; Yuuko Dai; Akiko Iwao; Yuki Jinnai
Journal:  J Surg Oncol       Date:  2013-12-06       Impact factor: 3.454

Review 10.  The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

Authors:  Chao Han; Ben Yang; Wen-Shu Zuo; Gang Zheng; Li Yang; Mei-Zhu Zheng
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

View more
  2 in total

1.  The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.

Authors:  M Noguchi; M Inokuchi; M Yokoi-Noguchi; E Morioka
Journal:  Breast Cancer       Date:  2021-09-30       Impact factor: 4.239

2.  Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes.

Authors:  Muriel Abbaci; Angelica Conversano; Maryam Karimi; Marie-Christine Mathieu; Valérie Rouffiac; Frederic De Leeuw; Stefan Michiels; Corinne Laplace-Builhé; Chafika Mazouni
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.